The launch edition of MedicalTech Innovation Forum, as Messe Frankfurt India’s first-ever hybrid conference was held at Visakhapatnam in October 2021. Experts from the healthcare industry discussed the need for optimum infrastructure, regulatory framework and innovation in the Indian medical devices industry. Aligning with India’s goal of becoming a global hub for medical device manufacturing and innovation, Messe Frankfurt India and Andhra Pradesh MedTech Zone (AMTZ) successfully launched the first edition of MedicalTech Innovation Forum (MIF) in October 2021 at Kalam Convention Centre, AMTZ Campus, Visakhapatnam. With 192 delegates under its roof, the forum united policy makers, national and international leaders from medical technology industry, academic and research fraternity to discuss major factors that impact the growth of the Indian medical devices industry, such as import dependency, need for more investment and collaborations. The two-day conference was inaugurated by prominent and renowned members from the world of healthcare, including: Dr Jitendra Sharma, Managing Director & Chief Executive Officer, Andhra Pradesh Medtech Zone Dr Uma Nambiar, Managing Director, Zeeden Life Sciences & Chairperson, DHIA Dr Manoj Chugh, Vice President & Head, Research and Development (Reagents), Transasia Bio-Medicals Ltd. Sudhakar Mairpadi, Head – Quality, Regulatory and Govt. Affairs, Philips India Ltd. Dr Anand Krishnan, Chief Executive Officer, Medivalley Incubation Council, Andhra Pradesh Medtech Zone Dilip Kumar, Chief Executive Officer, Biovalley Incubation Council, Andhra Pradesh Medtech Zone Ryou Jung-Suk, Managing Director – India, Cube Medical – Korea and Managing Director, IDTA (International Incurable Disease Treatment Association) Dr Nambiar shared, “India, as we all know, is the pharmacy of the world. We are also very well known for a good and economical healthcare system, so it’s only natural that the next arena for us to conquer in India would be the industry of medical devices. For various reasons we have not yet reached where we should because the big companies are traditionally centred in the west, but we have been outsourcing the devices to a lot of companies.” “However, we have seen revolution of sorts in the last two years. Owing to Government’s focus on ‘Aatmanirbhar Bharat’ and making India self-sufficient in many things related to healthcare, we have seen India transform from an importer of consumables in infectious disease treatment to the second largest exporter in the world within a span of one year. The same fate will also ensue in the medical devices industry.” Dr Nambiar further said that improvement of regulatory framework in India and encouragement towards innovation in medical devices from the government’s behalf will be the next best thing that is going to happen in the healthcare industry. Elaborating on the glowing opportunities that exist in the medical technology space, Dr Srikanth Sola, Founder, CEO and Director, Devic Earth Pvt Ltd, shared, “Within medical devices there are opportunities in diagnostics across adult paediatric ranges particularly in areas such as oncology, radiology, cardiology and other major specialties. There are also opportunities within medical therapeutics, devices, treatments and algorithms that help to predict when a patient is about to fall sick and help them get better. These devices include treatments that can be used in the hospital, within healthcare facilities for outpatient use and at home.” Abhijeet Ghosh, Assistant Drugs Controller (Medical Devices), Central Drugs Standard Control Organisation (CDSCO), who was a part of the prestigious dais, also shared: “There is a lot of scope in the field of medical devices but it is also crucial to set up proper regulations first.” “Conferences like these are vital to stimulate interactions between start-ups, manufacturers and regulators which will help the government to understand the needs of industry players. I hope that the organisers will continue to host events as such for the betterment of Indian medical devices industry.” India’s aim to overcome the excess of imports and become an independent producer of medical devices and medical technology can only be realised by promoting localisation, empowering start-ups and setting-up medtech research and authentication centres to approve and certify standardised medical devices, and eliminate counterfeiting from the supply chain. Overall, the joint cooperation between Messe Frankfurt India and AMTZ, through the launch of MedicalTech Innovation Forum, went a long way to discuss a clear collaborative approach and to project a roadmap for the medical devices industry in India to follow in the long run.
Chennai: In an effort to meet the demand for oxygen across the country, Uber has announced a partnership with Andhra Pradesh MedTech Zone Limited (AMTZ) for providing an on-demand rental delivery service of life-saving oxygen concentrators to citizens across 12 cities. Covid positive patients in home isolation will be able to rent oxygen concentrators through the O2Home app, at ‘an affordable price of Rs 300 to 400 per day,’ Uber said. “Uber’s free mobility support will enable convenient, swift and safe doorstep delivery of these oxygen concentrators to help save lives.” The service is operational across 12 Indian cities including Visakhapatnam, Lucknow, Hyderabad, Indore, Coimbatore, Guwahati, Nagpur, Bhubaneswar, Bengaluru, Pune, Jaipur and Raipur.
The new facility was virtually inaugurated today by Shri Mekapati Goutham Reddy, Hon’ble Minister for Industries, Commerce & IT, Andhra Pradesh; Dr. P D Vaghela, Chairperson, Telecommunications Regulatory Authority of India (TRAI) and Dr. Arabinda Mitra, Scientific Secretary to Principal Scientific Adviser, Govt. of India; Sri R. Karikal Valaven, Special Chief Secretary to Government, Industries & Commerce in the presence of Dr. Jitendra Sharma, MD & CEO, AMTZ, Suresh Vazirani, Founder & Chairman, Transasia-Erba International Group of Companies and Dr. Manoj Chugh, Vice President, R&D Reagents, Transasia Bio-Medicals Ltd. Transasia’s 5th manufacturing facility in India besides plants in Baddi, Daman, Sikkim and Mumbai, the new facility entailed initial investment of over 30 crore. Truly integrated, the facility with an annual capacity of 2 million Molecular & Serology test kits has face recognition system, cold room, storage area, clean rooms of BSL-II/BSL-III grade, large lyophilizers, protein purification equipment, advanced QC equipment and automated machines. The facility will significantly reduce India’s current import dependence for such testing kits. In his comments, Suresh Vazirani, Founder & Chairman, Transasia-Erba International Group of Companies, said, “We are truly delighted to partner AMTZ under the visionary leadership of Dr. Jitendra Sharma, in contributing our bit to realize the dream of making India atmanirbhar and a global export hub for IVD products and solutions. With worldclass infrastructure for manufacturing, testing and certification of medical devices available in the park, the facility would play a key role in import substitution of medical devices. The new facility reinforces Transasia’s track record of enabling better healthcare outcomes for over 40 years by offering total solutions for clinical diagnosis.” “We are pleased that Transasia chose AMTZ to set up Asia’s largest IVD manufacturing facility. It gives me further pleasure being there for the inauguration of Transasia’s world-class IVD manufacturing facility. Addition of this facility further enhances AMTZ appeal as an ecosystem with huge upsides for industry players. Wholeheartedly congratulate Mr. Vazirani and the Transasia team for this worldclass facility,” added Dr. Jitendra Sharma, MD & CEO of AMTZ. In his comments, Dr. Manoj Chugh, Vice President, R&D Reagents, Transasia Bio-Medicals Ltd., said, “Several new offerings are on the anvil as we step up to meet the diagnostic needs of doctors and patients. The plant will have the flexibility to scale up manufacturing capabilities on demand, while driving greater operational efficiency.” Operations will start immediately at this new plant with product roll outs expected in early September. The new facility has the capacity to produce 6 lakh Elisa-based antibody detection test kits per day besides RT-PCR and rapid test kits. To address the growing need for serological tests as disease prevention spurred by greater awareness of infectious diseases due to covid-19, this facility will manufacture testing kits for other immunology products as well. To meet the growing demand, Transasia will significantly invest in R&D and manpower at the facility for its immunology products with total hiring estimated at 500 employees as of now.
Transasia Bio-Medicals Ltd. on Thursday announced the formal inauguration of its state-of-the-art medical devices manufacturing plant at the Andhra Pradesh MedTech Zone (AMTZ) here. The largest of its kind facility in Asia spread over 35,000 sft will manufacture ErbaLisa COVID-19 IgG ELISA test kits, RT-PCR kits and rapid test kits for India and other emerging markets. The new facility was virtually inaugurated by Minister for Industries, Commerce and IT Mekapati Goutham Reddy, Telecommunications Regulatory Authority of India (TRAI) chairperson P.D. Vaghela, Scientific Secretary to Principal Scientific Adviser, Government of India, Arabinda Mitra, Special Chief Secretary to Government (Industries and Commerce) R. Karikal Valven, in the presence of MD and CEO of AMTZ Jitendra Sharma, founder and chairman of Transasia-Erba International Group of Companies Suresh Vazirani and vice-president, R&D Reagents, Transasia Bio-Medicals Ltd. Manoj Chugh.
Sensing the impact of 3D printing on the healthcare sector and the future implications of the technology, the Andhra Pradesh MedTech Zone (AMTZ), on the 8th of March, 2021, inaugurated its 3D Bioprinting facility to develop artificial organs through 3D Bioprinting under the Bio Harmonised Aids for Rehabilitation and Treatment (BHARAT) programme to boost diagnostics and therapy. The Andhra Pradesh MedTech Zone is India’s first medical device park is a flagship project of the Government of Andhra Pradesh to manufacture indigenous medical technology products in the country and make healthcare accessible to the common man. One of the highlight companies of the MedTech zone is think3D, one of India’s largest 3D printing service providers. Think3D has a 17,500 square feet facility in the AMTZ that focuses primarily on medical devices but also serves many other sectors including aerospace, maritime, automotive, architecture, prototyping, etc. 3D printing is an innovative technology that encompasses all medical disciplines and offers new opportunities in diagnostics and therapy. From diagnostic visualization to surgical planning patient-specific models will provide an added value for patients and physicians as part of the initiative. The inauguration was attended by eminent guests like Dr. Jitendra Sharma(MD& CEO, AMTZ), Miss Mohini (Scientist B at BioValley Incubation Council, AMTZ), Raja Sekhar Upputuri (Co-founder &CEO, think3D, AMTZ), P S Chandranand (CEO, Biovalley InCubation Council, AMTZ) Anand Krishnan (CEO, Medivalley Incubation Centre, AMTZ) Ms Sangeetha (Production Manager, DNA Xperts Pvt Ltd, AMTZ )